Malaria Diagnostics Market is expected to reach US$ 1,200.24 million by 2030

Rapid Diagnostic Tests (RDTs)Segment to Hold Significant Share of Malaria Diagnostics Market During 2022–2030  

According to our latest study on "Malaria Diagnostics Market Forecast to 2030 – Global Analysis – by Technology and End User," the malaria diagnostics market value is expected to reach US$ 1,200.24 million by 2030 from US$ 782.57 million in 2022. The report emphasizes the key factors driving the market and prominent players with their developments. The increasing prevalence of malaria, and government initiatives to raise awareness of malaria diagnostics and treatment are the key factors bolstering the market growth. However, the limited number of WHO-prequalified products hinders the malaria diagnostics market growth.

Technological advancements in malaria diagnostic techniques, the introduction of new products, and other business expansion strategies (collaborations, and mergers and acquisitions) are the major factors benefiting the malaria diagnostics market. In July 2022, Mylab Discovery Solutions introduced the PathoDetect Extended Monsoon Fever Panel, a combination RT-PCR test to screen for parasitic leishmaniasis and bacterial species that cause salmonellosis and malaria, as well as Zika, dengue, malaria, and leptospirosis. In June 2022, SC Johnson collaborated with the Global Fund to accelerate efforts for the elimination of malaria, a deadly yet preventable and treatable disease. The partnership would leverage SC Johnson’s core competencies in entomology to bring measurable and economic sustainability in malaria management in Burundi, the Democratic Republic of Congo, Kenya, Rwanda, South Sudan, Tanzania, Uganda, and Zanzibar. In December 2019, Access Bio and Global Good (a collaboration partner of the former) developed a new ultra-sensitive rapid diagnostic test (uRDT) that is five times more sensitive in identifying histidine-rich protein 2 (HRP2) antigens than currently available uRDTs. Additionally, a variety of tools have been created to improve malaria diagnosis. The Nanomal DNA Analyzer is an affordable, point-of-care (POC) handheld diagnostic nanotechnology tool, which is simple to use and takes little time to complete. In a couple of minutes, it analyses malaria DNA alterations using a range of validated nanotechnologies to confirm the diagnosis of malaria and uncover medication resistance in malaria parasites. Medication Events Monitoring Devices (MEMS) have also been used extensively to track medication adherence to antimalarial drugs.

Malaria Diagnostics Market, by Technology:

The malaria diagnostics market, by technology, is segmented into microscopy, rapid diagnostic tests (RDTs), and molecular diagnostic tests. The rapid diagnostic tests (RDTs) segment held the largest share of the market in 2022 and is projected to register the highest CAGR in the market during 2022–2030. By demonstrating the presence of malaria parasites in human blood, malaria rapid diagnostic tests (RDTs) aid in the diagnosis of malaria. RDTs offer an alternative to clinically based diagnosis or microscopy, especially in situations when access to high-quality microscopy services is limited. Plasmodium falciparum or P. vivax is the only species that certain RDTs can identify, but others can identify four species: P. falciparum, P. vivax, P. malariae, and P. ovale. Usually, a finger prick is used to draw blood for the test.

Microscopy continues to be a crucial tool in malaria research studies and diagnosis. It is expected to remain relevant in drug efficacy monitoring as the initial signs of resistance to antimalarial drugs are commonly seen first through a reduction in parasite clearance rate. Moreover, a majority share of laboratory scientists is familiar with microscopy because it is a well-established and reasonably easy method, and the results of the microscopic tests might be obtained several hours after the blood is drawn (which eliminates latency).

Many new malaria diagnostic techniques have been developed since the World Health Organization’s (WHO) announcement of the urgent need for new, straightforward, rapid, accurate, and affordable diagnostic tests to overcome the limitations of light microscopy in determining the presence of malaria parasites. As a result, rapid diagnostic tests (RDTs) are increasingly being used in the diagnosis of malaria. RDTs are quick and simple, and they do not require electricity or specialized equipment. There are currently 28 distinct manufacturers offering 86 different malaria RDTs.

Malaria Diagnostics Market, by End User:

The malaria diagnostics market, by end user, is segmented into hospitals and clinics, diagnostic centers, and others. The hospitals and clinics segment held the largest market share in 2022. hospitals and clinics provide enhanced care services to community members and support primary care. The malaria diagnostics market for the hospitals and clinics segment is driven by growing public–private partnerships in the healthcare sector, in addition to the increasing incidences of malaria. The rapidly evolving hospitals and clinics industry is changing the face of this sector. The hospitals and clinics is backed by specialized infrastructure and medical personnel specialized in providing quality care, would continue to drive the market growth for this segment in the coming years. Further, the growing emphasis on the usage of RDTs for their rapid turnaround times, low costs, and convenient accessibility is one of the main causes of the dominance of clinics in the malaria diagnostics market.

Access Bio., Inc.; Abbott Laboratories; Premier Medical Corporation Pvt. Ltd.; Sysmex Partec GmbH; bioMerieux; Beckman Coulter Inc.; Siemens Healthineers; Leica Microsystems GmbH; Nikon Corporation; Olympus Corporation; and Bio-Rad Laboratories Inc. are among the leading companies operating in the malaria diagnostics market.

The report segments the malaria diagnostics market as follows:

Based on technology, the malaria diagnostics market is segmented into microscopy, rapid diagnostic tests (RDTs), and molecular diagnostic tests. Based on end user, the market is segmented into clinics, hospitals, and diagnostic centers. By geography, the malaria treatment market is segmented into North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia Pacific), the Middle East & Africa (Saudi Arabia, UAE, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com